Adaptative Strategy of Immunosuppressive Drugs Dosage Adjustments When Combined With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients With COVID-19.

drug monitoring drug-drug interactions nirmatrelvir/ritonavir pharmacokinetic modelling tacrolimus

Journal

Transplant international : official journal of the European Society for Organ Transplantation
ISSN: 1432-2277
Titre abrégé: Transpl Int
Pays: Switzerland
ID NLM: 8908516

Informations de publication

Date de publication:
2024
Historique:
received: 02 11 2023
accepted: 11 03 2024
medline: 10 4 2024
pubmed: 10 4 2024
entrez: 10 4 2024
Statut: epublish

Résumé

Nirmatrelvir/ritonavir is a promising option for preventing severe COVID-19 in solid organ transplant recipients with SARS-CoV-2 infection. However, concerns have arisen regarding potential drug interactions with calcineurin inhibitors (CNI). This two-phase multicentre retrospective study, involving 113 patients on tacrolimus and 13 on cyclosporine A, aimed to assess the feasibility and outcomes of recommendations issued by The French societies of transplantation (SFT) and pharmacology (SFPT) for CNI management in this context. The study first evaluated adherence to recommendations, CNI exposure, and clinical outcomes. Notably, 96.5% of patients on tacrolimus adhered to the recommendations, maintaining stable tacrolimus trough concentrations (C

Identifiants

pubmed: 38596505
doi: 10.3389/ti.2024.12360
pii: 12360
pmc: PMC11002075
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

12360

Informations de copyright

Copyright © 2024 Boland, Devresse, Monchaud, Briol, Belaiche, Giguet, Couzi, Thaunat, Esposito, Meszaros, Roussoulieres, Haufroid, Le Meur and Lemaitre.

Déclaration de conflit d'intérêts

AD reports consultancy fees from Alnylam and Merck outside the submitted work. CM reports research grants (paid to institution), financial support for participation in congresses, and expertise fees from Chiesi and Astellas. StB received lecture fees from Astellas. BG reports financial support for participation in congresses from Chiesi and Gilead, speaker for Gilead, outside the submitted work. LC received lecture fees from Astellas, Chiesi, Novartis, Sandoz, Ostuka, GSK, and Biotest, and participated in advisory boards for Biotest, Hansa, and Novartis. LE received fees from Astellas, Chiesi, and Sandoz. FL received research grants (paid to institution) from Astellas, Sandoz, and Chiesi and fees to attend meetings from Viiv, MSD, Janssen-Cilag, Pfizer, and Gilead. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Lidvine Boland (L)

Department of Clinical Chemistry, Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert, Belgium.
Louvain Centre for Toxicology and Applied Pharmacology (LTAP), Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Louvain-la-Neuve, Belgium.

Arnaud Devresse (A)

Department of Nephrology, Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert, Belgium.

Caroline Monchaud (C)

Service de Pharmacologie, Toxicologie et Pharmacovigilance, Centre Hospitalier Universitaire de Limoges, Limoges, France.
INSERM U1248 Pharmacology and Transplantation, Limoges, France.
FHU SUPORT, Limoges, France.

Sébastien Briol (S)

Department of Nephrology, Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert, Belgium.

Stéphanie Belaiche (S)

Department of Pharmacy, Lille University Medical Center, Lille, France.
Department of Hepatograstroenterology, Lille University Medical Center, Lille, France.
ULR2694-METRICS, Université de Lille, Lille, France.

Baptiste Giguet (B)

Liver Disease Department, Centre Hospitalo-Universitaire Pontchaillou, Rennes, France.

Lionel Couzi (L)

Department of Nephrology, Transplantation, Dialysis and Apheresis, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.

Olivier Thaunat (O)

Department of Transplantation, Nephrology and Clinical Immunology, Hospices Civils de Lyon, Lyon, France.

Laure Esposito (L)

Department of Nephrology, Dialysis and Organ Transplantation, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.

Magdalena Meszaros (M)

Hepatogastroenterology and Liver Transplant Unit, Saint Eloi Hospital, Centre Hospitalier Universitaire de Montpellier, Montpellier, France.

Ana Roussoulieres (A)

Department of Cardiology, Pulmonary Vascular Diseases and Heart Failure Clinic, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium.

Vincent Haufroid (V)

Department of Clinical Chemistry, Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert, Belgium.
Louvain Centre for Toxicology and Applied Pharmacology (LTAP), Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Louvain-la-Neuve, Belgium.

Yannick Le Meur (Y)

Department of Nephrology, Centre Hospitalier Regional Universitaire (CHU) de Brest, Brest, France.
INSERM UMR1227 Lymphocytes B et Autoimmunité, Université de Bretagne Occidentale, Brest, France.

Florian Lemaitre (F)

INSERM UMRS1085, Centre Hospitalier Universitaire (CHU) de Rennes, Rennes, France.
FHU SUPORT, Rennes, France.

Classifications MeSH